Drug Recommendations, Presentations, Marketing Authorizations, and Board Appointments - Research Report on Johnson & Johnson,

   Drug Recommendations, Presentations, Marketing Authorizations, and Board
 Appointments - Research Report on Johnson & Johnson, Lilly, Sanofi, GSK, and
                                    Pacira

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, September 25, 2013

NEW YORK, September 25, 2013 /PRNewswire/ --

Today, Analysts Corner announced new research reports highlighting Johnson &
Johnson (NYSE: JNJ), Eli Lilly and Company (NYSE: LLY), Sanofi (NYSE: SNY),
GlaxoSmithKline plc (NYSE: GSK), and Pacira Pharmaceuticals, Inc. (NASDAQ:
PCRX). Today's readers may access these reports free of charge - including
full price targets, industry analysis and analyst ratings - via the links
below.

Johnson & Johnson Research Report

On September 20, 2013, Janssen-Cilag International NV (Janssen), a
pharmaceutical company of Johnson & Johnson, announced that it has been
granted a positive opinion from the Committee for Medicinal Products for Human
Use (CHMP) recommending approval of INVOKANA in the European Union. According
to the Company, INVOKANA has been recommended for the treatment of adults with
type 2 diabetes mellitus, to improve glycaemic control. Jane Griffiths,
Company Group Chairman of Janssen Europe, Middle-East, Africa, stated, "This
positive opinion from the CHMP represents a major milestone in Johnson &
Johnson's longstanding commitment to diabetes. If approved, INVOKANA will pave
the way for Janssen as part of our goal to develop and provide new therapeutic
options for adult patients with type 2 diabetes." The Full Research Report on
Johnson & Johnson - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/07a8_JNJ]

--

Eli Lilly and Company Research Report

On September 17, 2013, Eli Lilly and Company (Lilly) and Boehringer Ingelheim
announced that the two companies will feature five oral and 12 poster
presentations for linagliptin and the investigational compound empagliflozin
at the 49th Annual Meeting of the European Association for the Study of
Diabetes (EASD) in Barcelona, to be held from September 23, 2013 to September
27, 2013. The Company reported that eight clinical abstracts for empagliflozin
and nine clinical and pre-clinical abstracts for linagliptin will be presented
at the Annual Meeting. According to the Company, empagliflozin is a sodium
glucose co-transporter 2 (SGLT2) inhibitor being investigated for the
reduction of blood glucose levels in adults with type 2 diabetes (T2D), while
linagliptin is an inhibitor of the enzyme, dipeptidyl peptidase-4 (DPP-4),
which breaks down the incretin hormones glucagon-like peptide-1 (GLP-1) and
glucose-dependent insulinotropic polypeptide (GIP) that are involved with
regulating blood sugar. The Full Research Report on Eli Lilly and Company -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/977d_LLY]

--

Sanofi Research Report

On September 17, 2013, Sanofi and its subsidiary Genzyme announced that
Lemtrada™ has been granted a marketing authorization by the European
Commission. According to the Company, Lemtrada is indicated for the treatment
of adult patients with relapsing remitting multiple sclerosis (RRMS) with
active disease defined by clinical or imaging features. David Meeker, M.D.,
President and CEO of Genzyme, stated, "The approvals of Lemtrada and Aubagio
in the European Union represent an important milestone for Genzyme and
demonstrate our focus on scientific innovation and commitment to multiple
sclerosis Patients." Meeker continued, "This is particularly exciting as the
EU approval is the first for Lemtrada globally. We look forward to making
these unique therapies available to MS patients very soon." The Full Research
Report on Sanofi - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/29ea_SNY]

--

GlaxoSmithKline plc Research Report

On September 19, 2013, GlaxoSmithKline plc (GSK) and Theravance announced that
European Medicines Agency's (EMA) Committee for Medicinal Products for Human
Use (CHMP) has released a positive opinion recommending marketing
authorization for fluticasone furoate/vilanterol (FF/VI) under the proposed
brand name RELVAR ELLIPTA. According to GSK, RELVAR ELLIPTA is used in the
regular treatment of asthma in adults and adolescents aged 12 years and older,
where use of a combination medicinal product (long-acting beta2-agonist and
inhaled corticosteroid) is appropriate; and for the symptomatic treatment of
adults with Chronic Obstructive Pulmonary Disease (COPD) with a FEV1<70%
predicted normal (post-bronchodilator) with an exacerbation history despite
regular bronchodilator therapy. Rick E Winningham, CEO of Theravance,
commented, "This is another key milestone in over a decade of joint
respiratory research and development between Theravance and GSK." The Full
Research Report on GlaxoSmithKline plc - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.AnalystsCorner.com/r/full_research_report/2a35_GSK]

--

Pacira Pharmaceuticals, Inc. Research Report

On September 12, 2013, Pacira Pharmaceuticals, Inc. (Pacira) announced the
appointments of Mark A. Kronenfeld, M.D. and Dennis L. Winger to the Board of
Directors. In addition, Pacira also announced that Luke Evnin, Managing
Director at MPM Capital, and Fred Middleton, General Manager at Sanderling
Ventures, will step down from the Board, effective September 30, 2013.
Commenting on the board changes, Dave Stack, President, CEO, and Chairman of
Pacira, said, "With their combined medical insight and deep expertise in
developing and implementing successful commercial strategies, we are looking
forward to working with them as we continue to execute on our own commercial
strategy for EXPAREL and enter into the next stage of growth as a company.
Additionally, we would like to recognize Luke and Fred for their innovative
vision in forming the company in 2007 and thank them for their unwavering
belief in our proprietary drug delivery technology and their thoughtful
guidance throughout the development and successful launch of EXPAREL." The
Full Research Report on Pacira Pharmaceuticals, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.AnalystsCorner.com/r/full_research_report/c0aa_PCRX]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, +1-310-496-8071 (North America)